Lonza has completed a US$15 million multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity. The expansion at the facility in Tampa, FL (US) will enable the site to provide more integrated services for customers across early-stage product development, clinical trial material manufacture and commercialisation of innovative drug products.
The Tampa site is part of Lonza’s global network for the design, development and manufacturing of drug substances and intermediates, particle engineering/bioavailability enhancement and drug products for oral and inhaled applications.
As part of the multi-year investment, the site now boasts a new fully equipped Product Development & QC Laboratory area with 13 processing suites and two new packaging suites. These facilities can support commercial packaging, including low-humidity environments and serialisation for complete tracking and tracing of commercial products.
The expansion included encapsulation and micro-dosing capabilities for Xcelodose Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing and Harro Hoefliger Modu-C capsule filling
The Swiss CDMO also revamped manufacturing with new suites and dedicated sampling and dispensing areas capable of handling highly potent compounds.
In addition, Lonza expanded and renovated the cGMP Manufacturing Cleanroom Facility, as well as completely renovating 25,000 sqft of the existing cGMP OSD Manufacturing Cleanroom Facility.
The expansion included encapsulation and micro-dosing capabilities for Xcelodose Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing and Harro Hoefliger Modu-C capsule filling.
Dr Christian Dowdeswell, VP & Head of Dosage Forms & Delivery Systems at Lonz, said: “Our Tampa site has an excellent track record of meeting the expedited timelines increasingly required in product development, and this investment allows us to further meet this challenge. The site has also had several successful domestic and international pre-approval inspections and our expansion allows us to fully support the commercialisation of these new products.”